4,008
Trials as lead sponsor
Most active programmes
The drugs appearing most often across GSK's recently active trials. Comparator arms are excluded.
- GSK57842838 trials
- Efimosfermin alfa6 trials
- Dostarlimab6 trials
- Depemokimab5 trials
- Belimumab4 trials
- Pembrolizumab4 trials
Upcoming readouts
Next primary completion dates among GSK's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Jan 2027A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-…Phase 3
- Mar 2027GLIDE: A Study of Depemokimab in Participants of 6 to 11 Years of AgePhase 3
- May 2027A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With BronchiectasisPhase 2
- Jun 2027A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOV…Phase 2
- Nov 2027A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)Phase 3
- Nov 2027DESTINY: Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety TrialPhase 3
Top therapeutic areas
Conditions studied most often across GSK's recently active trials.
- HIV Infections13 trials
- Asthma8 trials
- Pulmonary Disease, Chronic Obstructive5 trials
- Nasal Polyps5 trials
- Respiratory Syncytial Virus Infections5 trials
- Neoplasms4 trials
GSK pipeline by phase
The main study drugs across 192 active trials GSK leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 333 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Belantamab mafodotin | 19 | 3 | Feb 2029 est. | NCT06956170 · NCT06868667 · NCT06868654 |
| GSK5784283 | 8 | 2 | Apr 2027 est. | NCT07782996 · NCT07782970 · NCT07782957 |
| Efimosfermin alfa | 6 | 5 | Oct 2027 est. | NCT07704892 · NCT07701993 · NCT07221227 |
| Mocertatug rezetecan | 5 | 3 | Sept 2027 est. | NCT07694427 · NCT07684599 · NCT07286331 |
| Belimumab | 4 | 3 | Aug 2029 est. | NCT06716606 · NCT06572384 · NCT05878717 |
| CAB LA | 3 | — | Mar 2027 est. | NCT06134362 · NCT06741397 · NCT06786520 |
| Ris-Rez | 3 | 3 | Nov 2027 est. | NCT07099898 · NCT07602777 · NCT06551142 |
| BLU-5937 | 2 | 1 | Aug 2027 est. | NCT07650084 · NCT05600777 |
| Cabotegravir (CAB) tablet | 2 | — | — | NCT02951052 · NCT02938520 |
| Investigational varicella vaccine | 2 | 2 | Nov 2026 est. | NCT06806137 · NCT06693895 |
| RSVPreF3 OA vaccine | 2 | — | Sept 2026 est. | NCT07220109 · NCT06534892 |
| Velzatinib | 2 | 2 | Nov 2027 est. | NCT07585266 · NCT07689201 |
| BMS-663068 | 1 | — | — | NCT02362503 |
| CAB LA + RPV LA | 1 | — | — | NCT06694805 |
| CAB ULA | 1 | 1 | Sept 2029 est. | NCT07650916 |
| Cabotegravir Tablets | 1 | — | — | NCT03299049 |
| Candidate varicella vaccine | 1 | 1 | — | NCT06855160 |
| Dolutegravir | 1 | — | — | NCT05979311 |
| dTpa | 1 | — | Nov 2026 est. | NCT07596199 |
| FF/UMEC/VI | 1 | 1 | Jan 2027 est. | NCT05757102 |
| Fostemsavir | 1 | 1 | Sept 2032 est. | NCT07393659 |
| HFA-152a | 1 | — | Feb 2027 est. | NCT07645248 |
| HZ/su vaccine | 1 | — | Aug 2027 est. | NCT05371080 |
| IDRX-42 | 1 | 1 | May 2028 est. | NCT07218926 |
| Investigational varicella vaccine_Lot 1 | 1 | 1 | Dec 2026 est. | NCT06740630 |
| Linerixibat | 1 | — | Sept 2026 est. | NCT04167358 |
| MMRVNS | 1 | 1 | Feb 2028 est. | NCT07406360 |
| MMRVNS vaccine | 1 | — | Jun 2028 est. | NCT07742644 |
| Mocertatug rezetecan (Mo-Rez) | 1 | — | May 2030 est. | NCT07684612 |
| mRNA Seasonal Flu vaccine | 1 | — | Jun 2028 est. | NCT07805707 |
| Risvutatug rezetecan (Ris-Rez) | 1 | — | Dec 2029 est. | NCT07802704 |
| RSVPreF3 OA investigational vaccine | 1 | — | — | NCT04732871 |
| Tafenoquine | 1 | 1 | — | NCT06666491 |
Phase 220 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Bepirovirsen | 3 | — | Apr 2027 est. | NCT06497504 · NCT04954859 · NCT07168356 |
| GSK3862995B | 3 | 2 | Dec 2026 est. | NCT07201051 · NCT07789899 · NCT06154837 |
| Momelotinib | 3 | 2 | Mar 2027 est. | NCT07569081 · NCT06847867 · NCT06517875 |
| Adjuvanted RSVPreF3 vaccine | 2 | — | Jan 2027 est. | NCT07712380 · NCT07092865 |
| Cobolimab | 2 | — | Oct 2026 est. | NCT04655976 · NCT06521567 |
| GSK4527226 | 2 | 1 | Sept 2026 est. | NCT07105709 · NCT06079190 |
| GSK4532990 | 2 | 1 | Nov 2027 est. | NCT06613698 · NCT05583344 |
| VH3810109 | 2 | — | Jan 2027 est. | NCT05996471 · NCT07053384 |
| VH4524184 | 2 | 2 | Jun 2027 est. | NCT07202546 · NCT07636928 |
| AltSonflex1-2-3 | 1 | — | Oct 2028 est. | NCT07320716 |
| Camlipixant | 1 | 1 | Mar 2027 est. | NCT07519395 |
| Daplusiran/Tomligisiran Dose Level 1 | 1 | — | May 2027 est. | NCT06537414 |
| Efimosfermin | 1 | 1 | Jul 2028 est. | NCT06920043 |
| Flu mRNA (Formulation B1) | 1 | — | — | NCT07204964 |
| GSK3772701 600 mg | 1 | — | Jul 2027 est. | NCT07545681 |
| Low dose of iNTS-TCV | 1 | 1 | Apr 2028 est. | NCT07286370 |
| MenABCWY vaccine | 1 | — | Mar 2027 est. | NCT05087056 |
| MMB | 1 | — | Dec 2026 est. | NCT03441113 |
| RTS,S/AS01E vaccine | 1 | 1 | Apr 2027 est. | NCT07036159 |
| VH4011499 | 1 | — | Jun 2032 est. | NCT07816250 |
Phase 141 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Pn-MAPS30plus | 3 | 1 | Dec 2026 est. | NCT07428759 · NCT07406347 · NCT07406334 |
| Gepotidacin | 2 | — | May 2027 est. | NCT07645235 · NCT07371429 |
| GSK4771261 | 2 | — | Sept 2026 est. | NCT07600450 · NCT06734234 |
| GSK5926371 | 2 | 1 | Mar 2028 est. | NCT07607925 · NCT07371468 |
| Risvutatug rezetecan | 2 | 1 | Jan 2028 est. | NCT07602855 · NCT06885034 |
| Aletekitug | 1 | — | Jul 2028 est. | NCT07747480 |
| Aletekitug (GSK1070806) | 1 | — | Jul 2028 est. | NCT07747467 |
| Belantamab | 1 | 1 | Aug 2028 est. | NCT05714839 |
| Belantamab SC | 1 | — | Aug 2027 est. | NCT07742527 |
| Cabotegravir 200 mg/mL | 1 | 1 | Jun 2027 est. | NCT05418868 |
| Cabotegravir long-acting | 1 | — | — | NCT06970223 |
| Candidate UTI vaccine low dose formulation 1 | 1 | 1 | May 2027 est. | NCT06702449 |
| Dolutegravir/Rilpivirine FDC | 1 | 1 | — | NCT05674656 |
| Ganfeborole | 1 | — | Nov 2026 est. | NCT07784894 |
| GSK4418959 | 1 | — | — | NCT06710847 |
| GSK4425689A SC | 1 | — | Apr 2028 est. | NCT07646353 |
| GSK4524101 | 1 | — | — | NCT06077877 |
| GSK4527363 | 1 | 1 | Jan 2028 est. | NCT06576271 |
| GSK4528287 | 1 | — | — | NCT06681181 |
| GSK5458514 | 1 | 1 | Oct 2027 est. | NCT06990880 |
| GSK5460025 | 1 | 1 | Sept 2028 est. | NCT07213609 |
| GSK5471713 | 1 | 1 | Mar 2028 est. | NCT07332455 |
| GSK5533524 | 1 | 1 | Feb 2029 est. | NCT07438782 |
| GSK5764227 | 1 | 1 | — | NCT07277270 |
| GSK6097608 | 1 | — | Dec 2026 est. | NCT04446351 |
| Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine | 1 | 1 | Dec 2026 est. | NCT07464314 |
| Low dose Strep A Alum | 1 | 1 | Jun 2027 est. | NCT07085702 |
| Midazolam (MDZ) | 1 | 1 | — | NCT07670377 |
| Mo-Rez | 1 | 1 | Jun 2027 est. | NCT06796907 |
| Oral CAB | 1 | 1 | Oct 2029 est. | NCT07275606 |
| Oral VH4524184 | 1 | 1 | Jan 2028 est. | NCT06310551 |
| Pan-Salmonella-with-Alum (Low dose) vaccine | 1 | 1 | Nov 2027 est. | NCT07663032 |
| PED-HZ/su | 1 | 1 | — | NCT04006808 |
| Remzistotug | 1 | — | Aug 2027 est. | NCT05277051 |
| RSV/hMPV_V low dose vaccine | 1 | 1 | Apr 2029 est. | NCT07628049 |
| Salbutamol HFA-152a | 1 | 1 | Feb 2027 est. | NCT06433921 |
| TSR-022 | 1 | — | Mar 2027 est. | NCT02817633 |
| VH4011499 low dose Injection | 1 | 1 | Aug 2028 est. | NCT06724640 |
| VH4367310 | 1 | — | Jan 2029 est. | NCT07818915 |
| VH4527079 | 1 | — | — | NCT06652958 |
| VH4770359 | 1 | 1 | May 2027 est. | NCT07525544 |
Phase 48 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Dostarlimab | 15 | 4 | Nov 2026 est. | NCT07652515 · NCT06897527 · NCT07740720 |
| Depemokimab | 9 | 8 | Sept 2026 est. | NCT07701967 · NCT07671001 · NCT07456033 |
| Niraparib | 5 | 1 | Dec 2026 est. | NCT06887933 · NCT04915755 · NCT03602859 |
| Belimumab (GSK1550188) | 1 | — | Jun 2027 est. | NCT06411249 |
| Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate | 1 | — | — | NCT06372496 |
| Mepolizumab | 1 | — | — | NCT06041386 |
| Recombinant zoster vaccine | 1 | 1 | Apr 2030 est. | NCT07502560 |
| rMenB+OMV NZ | 1 | — | — | NCT06113198 |
Derived from 192 active trials GSK leads; 192 name an intervention, folding into 102 phased drugs. This is ComplyRx's reading of the registry, not GSK's own pipeline disclosure.
GSK trials
The 50 most significant of GSK's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| RSV OA=ADJ=012An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 StudyNCT06534892RSVPreF3 OA vaccine | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 10,212 est. | 30 Sept 2026 |
| A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant WomenNCT07596199dTpa | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 102 est. | 23 Nov 2026 |
| A Study to Investigate the Repeat-dose Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With Ganfeborole in Female Participants of Non-childbearing PotentialNCT07784894Ganfeborole | Phase 1 | Not yet scored | OngoingNot yet recruiting | 28 est. | 24 Nov 2026 |
| A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney TransplantNCT07092865Adjuvanted RSVPreF3 vaccine | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 168 est. | 12 Jan 2027 |
| A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With AsthmaNCT05757102FF/UMEC/VI | Phase 3 | Locked · track to reveal | OngoingRecruiting | 292 est. | 26 Jan 2027 |
| A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster DoseNCT07406334Pn-MAPS30plus | Phase 1 | Locked · track to reveal | OngoingRecruiting | 45 est. | 22 Feb 2027 |
| GLIDEA Study of Depemokimab in Participants of 6 to 11 Years of AgeNCT07671001Depemokimab | Phase 3 | Not yet scored | OngoingRecruiting | 34 est. | 1 Mar 2027 |
| A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283NCT07712393GSK5784283 | Phase 1 | Not yet scored | OngoingRecruiting | 24 est. | 13 Apr 2027 |
| A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With BronchiectasisNCT07201051GSK3862995B | Phase 2 | Locked · track to reveal | OngoingRecruiting | 363 est. | 4 May 2027 |
| A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)NCT07202546VH4524184 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 186 est. | 11 Jun 2027 |
| Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)NCT07701967Depemokimab | Phase 4 | Locked · track to reveal | OngoingRecruiting | 28 est. | 28 Jun 2027 |
| A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young AdultsNCT07085702Low dose Strep A Alum | Phase 1 | Locked · track to reveal | OngoingRecruiting | 108 est. | 29 Jun 2027 |
| A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)NCT06411249Belimumab (GSK1550188) | Phase 4 | Locked · track to reveal | OngoingActive, not recruiting | 303 est. | 29 Jun 2027 |
| A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney DiseaseNCT06734234GSK4771261 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 86 est. | 23 Jul 2027 |
| DynaMMic-2A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of CareNCT07742527Belantamab SC | Phase 1 | Not yet scored | OngoingNot yet recruiting | 22 est. | 5 Aug 2027 |
| A Study to Investigate the Difference In Blood Levels of Camlipixant Between Different Camlipixant Formulation PrototypesNCT07684586Camlipixant | Phase 1 | Not yet scored | StoppedWithdrawn | 0 est. | 27 Aug 2027 |
| A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations in Healthy ParticipantsNCT07789899GSK3862995B | Phase 1 | Not yet scored | OngoingRecruiting | 24 est. | 7 Sept 2027 |
| A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)NCT07099898Ris-Rez | Phase 3 | Locked · track to reveal | OngoingRecruiting | 420 est. | 5 Nov 2027 |
| A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVGH) Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Young AdultsNCT07663032Pan-Salmonella-with-Alum (Low dose) vaccine | Phase 1 | Not yet scored | OngoingRecruiting | 196 est. | 14 Nov 2027 |
| A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)NCT07602777Ris-Rez | Phase 1 | Locked · track to reveal | OngoingRecruiting | 113 est. | 18 Nov 2027 |
| DESTINYDepemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety TrialNCT05334368Depemokimab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 109 est. | 24 Nov 2027 |
| STARLIGHTA Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver DiseaseNCT06613698GSK4532990 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 393 est. | 26 Nov 2027 |
| A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and PimitespibNCT07689201Velzatinib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 24 est. | 29 Nov 2027 |
| A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)NCT06885034Risvutatug Rezetecan | Phase 1 | Locked · track to reveal | OngoingRecruiting | 451 est. | 10 Jan 2028 |
| First Time in Human Study of Long Acting VH4524184 FormulationsNCT06310551Oral VH4524184 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 372 est. | 21 Jan 2028 |
| A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)NCT07286331Mocertatug rezetecan | Phase 3 | Locked · track to reveal | OngoingRecruiting | 600 est. | 29 Feb 2028 |
| ZENITH-2A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASHNCT07221188Efimosfermin Alfa | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,250 est. | 24 Mar 2028 |
| First-Time-in-Human Study of GSK5471713 in Adults With mCRPCNCT07332455GSK5471713 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 54 est. | 24 Mar 2028 |
| ZENITH-1A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASHNCT07221227Efimosfermin alfa | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,200 est. | 29 Mar 2028 |
| A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyNCT07218926IDRX-42 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 450 est. | 30 May 2028 |
| A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of AgeNCT07805707mRNA Seasonal Flu vaccine | Phase 3 | Not yet scored | OngoingNot yet recruiting | 54,000 est. | 9 Jun 2028 |
| MMRVNS 20-002A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of AgeNCT07742644MMRVNS vaccine | Phase 3 | Not yet scored | OngoingNot yet recruiting | 1,860 est. | 27 Jun 2028 |
| PEGASUSA Study to Investigate the Safety and Tolerability of Multiple Study Interventions in Participants With Moderate to Severe Ulcerative ColitisNCT07747467Aletekitug (GSK1070806) | Phase 1 | Not yet scored | OngoingNot yet recruiting | 16 est. | 31 Jul 2028 |
| A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative ColitisNCT07747480Aletekitug | Phase 1 | Not yet scored | OngoingNot yet recruiting | 16 est. | 31 Jul 2028 |
| DynaMMic-1A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination TreatmentsNCT05714839Belantamab | Phase 1 | Locked · track to reveal | OngoingRecruiting | 123 est. | 3 Aug 2028 |
| ALLSTARA Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)NCT07791043Efimosfermin alfa | Phase 2 | Not yet scored | OngoingNot yet recruiting | 274 est. | 5 Sept 2028 |
| A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumorsNCT07213609GSK5460025 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 47 est. | 28 Sept 2028 |
| A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of AgeNCT07406347Pn-MAPS30plus | Phase 1 | Locked · track to reveal | OngoingNot yet recruiting | 60 est. | 18 Oct 2028 |
| A Study to Investigate Pharmacokinetics (PK), Safety, and Tolerability of VH4367310 in Healthy Adult ParticipantsNCT07818915VH4367310 | Phase 1 | Not yet scored | OngoingNot yet recruiting | 112 est. | 2 Jan 2029 |
| First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid TumorsNCT07438782GSK5533524 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 97 est. | 6 Feb 2029 |
| A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1)NCT07780643GSK5784283 | Phase 3 | Not yet scored | OngoingNot yet recruiting | 514 est. | 15 Feb 2029 |
| PERSISTCRSwNP2A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)NCT07782957GSK5784283 | Phase 3 | Not yet scored | OngoingNot yet recruiting | 218 est. | 6 Mar 2029 |
| PERSISTCRSwNP1A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)NCT07782970GSK5784283 | Phase 3 | Not yet scored | OngoingNot yet recruiting | 218 est. | 6 Mar 2029 |
| PALISADELong-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)NCT06134362CAB LA | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 2,996 est. | 14 Mar 2029 |
| A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older AdultsNCT07628049RSV/hMPV_V low dose vaccine | Phase 1 | Not yet scored | OngoingRecruiting | 1,456 est. | 5 Apr 2029 |
| VIGILANTeValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 InflammationNCT07177339Depemokimab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,196 est. | 30 Apr 2029 |
| A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)NCT07782996GSK5784283 | Phase 3 | Not yet scored | OngoingNot yet recruiting | 370 est. | 4 May 2029 |
| A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular EventsNCT07712380Adjuvanted RZV vaccine | Phase 2 | Not yet scored | OngoingNot yet recruiting | 450 est. | 4 May 2029 |
| A Study to Investigate Safety, Tolerability and Pharmacokinetics of VH5356136 in Adult Participants Without HIVNCT07822477VH5356136 Formulation 1 | Phase 1 | Not yet scored | OngoingNot yet recruiting | 160 est. | 9 May 2029 |
| A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)NCT07602855Risvutatug rezetecan | Phase 1 | Locked · track to reveal | OngoingNot yet recruiting | 184 est. | 21 Jun 2029 |